trending Market Intelligence /marketintelligence/en/news-insights/trending/yqdojkdaxau2rttgvbn-va2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Aileron Therapeutics' chief medical, scientific officer becomes CEO

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Aileron Therapeutics' chief medical, scientific officer becomes CEO

Aileron Therapeutics Inc. appointed Manuel Aivado as president and CEO.

Aivado succeeds John Longenecker, who replaced Joseph Yanchik III on an interim basis after he resigned.

Aivado has been the senior vice president and chief medical and scientific officer of the biopharmaceutical company since 2012. He most recently designed and implemented the first-in-human trial of the company's experimental anti-tumor therapy ALRN-6924.